Journal Watch · Journal of Controlled Release · 2026
Phosphatase and tensin homolog mRNA complexed with hyaluronated lipid nanoparticles for transdermal cancer immunotherapy.
Taken together, these results highlight HA-LNP as a promising, clinically translatable platform for localized, mRNA-based cancer immunotherapy.
TL;DR
Taken together, these results highlight HA-LNP as a promising, clinically translatable platform for localized, mRNA-based cancer immunotherapy.
Key findings
- In vivo, topical application results in deep skin and tumor penetration, significantly inhibiting tumor growth and enhancing immune activation with minimal toxicity.
- Taken together, these results highlight HA-LNP as a promising, clinically translatable platform for localized, mRNA-based cancer immunotherapy.
What they did
This amphiphilic lipid enables stable HA integration during LNP self-assembly, effectively replacing PEG, supporting particle stability, biocompatibility, and CD44-mediated targeting. The resulting HA-LNP efficiently encapsulate large mRNA payloads, penetrate the skin, and selectively target CD44-expressing tumor cells. In vitro, PTEN mRNA@HA-LNP restores PTEN expression, induces immunogenic cell death (ICD), and reduces melanoma cell viability.
Full abstract (original)
Background: The loss of phosphatase and tensin homolog (PTEN) can lead to resistance to immune checkpoint inhibitors (ICIs) in melanoma, thereby promoting immune evasion and tumor progression. These effects can be reversed by restoring PTEN expression, reactivating antitumor immunity, and enhancing therapeutic responses. Here, we develop a hyaluronate-conjugated lipid nanoparticle (HA-LNP) with HA-dimyristoyl glycerol (DMG) for the non-invasive, transdermal delivery of PTEN mRNA.
What they did: This amphiphilic lipid enables stable HA integration during LNP self-assembly, effectively replacing PEG, supporting particle stability, biocompatibility, and CD44-mediated targeting. The resulting HA-LNP efficiently encapsulate large mRNA payloads, penetrate the skin, and selectively target CD44-expressing tumor cells. In vitro, PTEN mRNA@HA-LNP restores PTEN expression, induces immunogenic cell death (ICD), and reduces melanoma cell viability.
Results & conclusions: In vivo, topical application results in deep skin and tumor penetration, significantly inhibiting tumor growth and enhancing immune activation with minimal toxicity. Taken together, these results highlight HA-LNP as a promising, clinically translatable platform for localized, mRNA-based cancer immunotherapy.
Abstract © the authors / Journal of Controlled Release (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.jconrel.2025.114518 · PubMed 41386375.
Why it matters for pharma & biotech
- Directly relevant to teams in mRNA / delivery technology, targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: mRNA / delivery technology · targeted oncology / immuno-oncology · small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Journal of Controlled Release study find?
Taken together, these results highlight HA-LNP as a promising, clinically translatable platform for localized, mRNA-based cancer immunotherapy.
What type of study is this?
It is a in-vitro / cell study, published in Journal of Controlled Release in 2026. This amphiphilic lipid enables stable HA integration during LNP self-assembly, effectively replacing PEG, supporting particle stability, biocompatibility, and CD44-mediated targeting.
Where can I read the original paper?
The original is at the publisher via DOI 10.1016/j.jconrel.2025.114518. PubMed ID: 41386375. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/phosphatase-and-tensin-homolog-mrna-complexed-with-hyaluronated-lipid-na-114518/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides